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ABSTRACT
Sequence-specific endonucleases recognizing long
target sequences are emerging as powerful tools
for genome engineering. These endonucleases
could be used to correct deleterious mutations
or to inactivate viruses, in a new approach to molec-
ular medicine. However, such applications are
highly demanding in terms of safety. Mutations in
the human RAG1 gene cause severe combined
immunodeficiency (SCID). Using the I-CreI dimeric
LAGLIDADG meganuclease as a scaffold, we
describe here the engineering of a series of endo-
nucleases cleaving the human RAG1 gene, including
obligate heterodimers and single-chain molecules.
We show that a novel single-chain design, in which
two different monomers are linked to form a single
molecule, can induce high levels of recombination
while safeguarding more effectively against poten-
tial genotoxicity. We provide here the first demon-
stration that an engineered meganuclease can
induce targeted recombination at an endogenous
locus in up to 6% of transfected human cells.
These properties rank this new generation of
endonucleases among the best molecular scissors
available for genome surgery strategies, potentially
avoiding the deleterious effects of previous gene
therapy approaches.
INTRODUCTION
Meganucleases are endonucleases that recognize large
(>12bp) DNA sequences. They are often referred to as
homing endonucleases (HE) because the proteins are
encoded by mobile introns or inteins which propagate
via a process called homing. Their target sequence is usu-
ally found in homologous alleles lacking the intron or
intein. Cleavage of the target DNA sequence stimulates
a homologous recombination event resulting in the inser-
tion of the mobile genetic element into the DNA cleavage
site (1). The homing endonuclease I-SceI has also been
shown to stimulate targeted recombination in immorta-
lized mammalian cells (2,3) and in various cell types and
organisms (4). These results, together with the high speci-
ﬁcity of meganucleases, make these enzymes a tool of
choice for genome engineering. Until recently, the major
limitation of this approach was the absence of any cleav-
age sequences for natural meganucleases in the vicinity of
the locus of interest, and three diﬀerent strategies have
been envisioned for the generation of engineered artiﬁcial
endonucleases cleaving chosen sequences (5). Chimeric
endonucleases resulting from the fusion of engineered
zinc-ﬁngers domains with the catalytic domain of the
FokI restriction enzyme have been used to induce targeted
recombination in endogenous genes in human cells,
Drosophila, plants, ﬁsh and other organisms (6–12). In a
totally diﬀerent approach, triplex forming oligonucleo-
tides (TFOs) have been conjugated with chemical DNA
cleavers (13) or restriction enzymes (14) to target their
cleavage activity to speciﬁc long sequences. However,
the recent development of adapted protein-engineering
strategies (15–23) has opened the way to the development
of tailored endonucleases derived from natural HE.
HEs are classiﬁed in ﬁve families, of which the
LAGLIDADG family (named after a conserved peptide
motif) is the largest and best characterized one (24).
Proteins with one LAGLIDADG motif in their primary
sequence, such as I-CreI or I-MsoI form homodimers
and cleave palindromic or pseudo-palindromic sequences,
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I-DmoI, are single-chain proteins, that cleave non-
palindromictargets(25).Thestructuresofseveralmembers
of this family have been solved (26–30), showing a strong
conservation of the core structure. The LAGLIDADG
motifs are part of the conserved a-helices constituting the
main interface between the two monomers or the two
domains of a single-chain protein. Each of the monomers
or the domains adopts a characteristic abbabba fold and
DNA recognition and binding is dependent on the four-
stranded antiparallel b-sheets, which form a saddle on the
major groove of the DNA helix. In addition, structures of
the complexes formed between the endonuclease and
cleaved or uncleaved forms of the DNA target have pro-
vided insight into the catalytic mechanism underlying
hydrolysis of the two phosphodiester bonds (31).
We have already described how, by adopting a semi-
rational combinatorial strategy, we were able to design
I-CreI variant proteins that were able to cleave DNA
targets of interest, including DNA sequences located
in the human RAG1 and XPC genes in particular
(15,32,33). The non-palindromic DNA sequence is cleaved
following the co-expression of two I-CreI variants, each of
them recognizing one-half of the DNA target. The two
proteins can associate as a heterodimer, which binds and
cleaves the DNA target. Nevertheless, the co-production
of two I-CreI derived proteins results in the presence
of three molecular species in the cell: the heterodimer
and both homodimers. The two homodimers may be con-
sidered to be by-products with the potential to aﬀect the
overall meganuclease speciﬁcity, a particularly crucial
aspect for therapeutic applications (4). Two possible stra-
tegies for overcoming the problem of homodimer forma-
tion could be envisaged. The ﬁrst involves engineering
the protein interface between the two monomers to
impair the formation of functional homodimers and
favor heterodimer formation. This strategy for designing
an obligate heterodimer has already been described for
zinc-ﬁnger nucleases (34,35) and for I-CreI derived mega-
nucleases (36). This strategy is still limited by the need to
co-transfect cells with two plasmids, making it impossible
to control the stoichiometry of the two monomers. The
second strategy would involve mimicking natural evolu-
tion by creating a single-chain molecule. This approach
has already been successfully applied to I-CreI and
I-MsoI proteins (37,38). The single-chain design would
not only abolish homodimer activity, but would also facil-
itate transfection and resolve stoichiometry problems.
We describe here the engineering of obligate heterodimers
and single-chain variants of I-CreI for targeting the
human RAG1 gene. These two designs result in meganu-
cleases with high levels of activity in vivo against the target
sequence and an absence of homodimer activity.
The lymphoid-speciﬁc Rag1 protein is essential for the
V(D)J recombination process, which generates the diver-
sity of the immune repertoire. The disruption of Rag1
function leads to a severe combined immunodeﬁciency
(SCID), with a complete absence of mature B and T
cells (39). The induction of a homologous recombination
mechanism following the creation of a DNA double
strand break (DSB) by a speciﬁc meganuclease could
correct RAG1 mutations and lead to reversion to a
normal phenotype. However, this approach to genome
engineering for therapeutic purposes requires the highest
possible level of meganuclease speciﬁcity. Therefore, we
designed obligate heterodimer and single-chain versions
of the RAG1 meganuclease. The protein activity and tox-
icity of each RAG meganuclease were assessed in various
assays, and both designs appeared to result in signiﬁcantly
lower levels of toxicity, while preserving or even enhancing
activity. The best properties were displayed by single-
chain molecules, which were used to induce high levels
of recombination (up to 6%) in the endogenous human
RAG1 gene in 293 cells, demonstrating the full potential
of this technology. Thus the single chain appears to be the
scaﬀold of choice to undertake the genomic correction of
mutations present in the human genome for gene therapy
in SCID and other monogenic diseases.
MATERIALS AND METHODS
Construction of target clones
The 22-bp LR target found in the human RAG1 gene
(TGTTCTCAGGTACCTCAGCCAG), the two palindro-
mic derivative targets LL (TGTTCTCAGGTACCTGAG
AACA) and RR (CTGGCTGAGGTACCTCAGCCAG)
were cloned as follows: oligonucleotides containing the
target site (Proligo) were ampliﬁed by PCR to generate
double-stranded target DNA and then inserted into repor-
ter vectors with the Gateway protocol (Invitrogen): the
yeast vector pFL39-ADH-LACURAZ and the mamma-
lian vector pcDNA3.1-LAACZ, both previously described
and containing an I-SceI target site as a control. Yeast
reporter vectors were used to transform Saccharomyces
cerevisiae strain FYBL2-7B (MAT a, ura3851,
trp163, leu21, lys2202).
Construction of the single-chain molecule
One single-chain molecule contains two almost identical
sequences, encoding the I-CreI derived V2 and V3
mutants. The two coding sequences are diﬀerent, display-
ing only 72% nucleic acid sequence identity, thereby
avoiding problems relating to construct stability. The
N-terminal half of the single-chain molecules contains
a full length I-CreI molecule of 163 residues, whereas
the C-terminal sequence lacks the ﬁrst ﬁve residues.
Various linkers were used to connect the two mutant pro-
teins (Table 1).
Meganuclease production
The ORFs encoding the various meganucleases were
ampliﬁed by PCR and inserted into the 2mm-based repli-
cative vector pCLS542, harboring the LEU2 gene.
Saccharomyces cerevisiae strain FYC2-6A (MATa,
trp163, leu21, his3200) was then transformed with
the vector using a high-eﬃciency lithium acetate transfor-
mation protocol. The various meganuclease genes were
also inserted into the mammalian vector pcDNA3.1.
The genes were expressed under the control of a CMV
promoter. Protein production in CHO-K1 cells was
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(KETAAAKFERQHMDS) epitope to the C-terminus of
the protein. Cells were harvested 48h after the transfection
of the cells using the Polyfect reagent (Qiagen) and directly
solubilized in Laemmli buﬀer (100ml of buﬀer for 10
6
cells). The equivalent of 10
5 cells was loaded on a SDS–
PAGE gel and probed by western blot using an anti-HA
antibody (Roche) or an anti-S-Tag antibody (Santa Cruz).
Purification of meganucleases
For the production of heterodimeric I-CreI derivatives,
the ORFs of each of the monomers were inserted into
the CDFDuet-1 vector (Novagen) with a 6xHis tag or a
Strep tag at the C-terminus. The double-tagged heterodi-
mers were produced and puriﬁed as previously described
(30). The protein was concentrated to about 15mg/ml,
ﬂash-frozen in liquid nitrogen and stored at  808C.
Protein concentration was determined by measuring
absorbance at 280nm. Sample purity was checked by
SDS–PAGE and heterodimer formation was assessed by
western blotting with an anti-His or an anti-Strep tag anti-
body and conﬁrmed by mass spectrometry. All the puri-
ﬁed proteins were found to have adopted a structure
similar to that of the wild type (as shown by circular
dichroism and NMR) and to be dimeric in solution (as
shown by analytical ultracentrifugation: data not shown).
The sequence encoding the single-chain scV3-V2(G19S)
protein with a 6xHis tag at the C-terminus was inserted
into the pET24d(+) vector and expressed in Escherichia
coli Rosetta(DE3)pLysS cells (Novagen) grown in LB
supplemented with kanamycin and chloramphenicol.
Induction with IPTG for 5h at 378C or for 15h at 208C
yielded high levels of expression, however, after sonication
in lysis buﬀer containing 50mM sodium phosphate pH
8.0, 300mM NaCl, 5% glycerol and protease inhibitors
(Complete EDTA-Free tablets, Roche) and ultracentrifu-
gation at 20000 g for 1h, the protein was found exclu-
sively in the insoluble fraction as determined by western
blots with an anti-His antibody. The protein was therefore
puriﬁed under denaturing conditions by ﬁrst solubilizing it
in lysis buﬀer supplemented with 8M urea. After clariﬁ-
cation by ultracentrifugation (2h at 40000 g) the sample
was applied onto a column packed with Q-Sepharose XL
resin (GE Healthcare) equilibrated with the same buﬀer.
This puriﬁcation step separated all the nucleic acids
(retained in the column) from the protein and improved
the performance of subsequent puriﬁcation steps. The pro-
tein was recovered from the ﬂow through on a Co
2+-
loaded HiTrap Chelating HP 5ml column (GE
Healthcare) equilibrated with the lysis buﬀer plus 8M
urea. After sample loading and column washing the pro-
tein was eluted with the same buﬀer supplemented with
0.5M imidazol. Protein-rich fractions (as determined by
SDS–PAGE) were collected and allowed to undergo
refolding, through a 20-fold dilution (drop by drop) with
20mM sodium phosphate pH 6.0, 300mM NaCl at 48C
(ﬁnal protein concentration of 0.13mg/ml). The refolded
protein was loaded onto a 5ml HiTrap heparin column
equilibrated with the same buﬀer and eluted with a gradi-
ent to 1M NaCl. The fractions containing the pure
protein were pooled, concentrated up to 1.4mg/ml
(35.6mM, determined by absorbance at 280nm) and
were either used immediately or ﬂash frozen in liquid
nitrogen and stored at  808C. The identity of the protein
was conﬁrmed by mass spectrometry which showed that
the initial methionine was absent from the puriﬁed poly-
peptide chain. The puriﬁed protein was found to be folded
into a structure similar to that of the wild type by circular
dichroism and NMR (data not shown), and to be mono-
meric in solution by analytical gel ﬁltration.
In vitro cleavage assay conditions
Cleavage assays were performed at 378C in 10mM Tris–
HCl pH 8, 50mM NaCl, 10mM MgCl2. The target
concentration was 2 nM (target substrates in plasmid
pGEM-T linearized with XmnI) and the protein concen-
trations were 120 (for cleavage detection) and 120, 90, 60,
40, 30, 20, 10, 7.5, 5, 3.5, 2, 1, 0.5, 0.25 and 0 nM for the
quantiﬁcation of cleavage eﬃciency, in a ﬁnal reaction
volume of 25–50ml. Reactions were stopped after 1h,
adding 5ml of 45% glycerol, 95mM EDTA (pH 8),
1.5% (w/v) SDS, 1.5mg/ml proteinase K and 0.048%
(w/v) bromophenol blue (6  stop buﬀer) and incubating
at 378C for 30min. The products of the reaction were
subjected to electrophoresis in a 1% agarose gel. The
gels were stained with SYBR Safe DNA gel staining
kits (Invitrogen) and the intensity of the bands observed
upon illumination with UV light was determined with
the ImageJ software (http://rsb.info.nih.gov/ij/). The line-
arized target plasmid was 3kb in size and yielded two
smaller bands, of 2kb and 1kb, upon cleavage with
the meganuclease. The percentage of cleavage was calcu-
lated with the following equation: % cleavage=100 
(I2kb+I1kb)/(I3kb+I2kb+I1kb), where I1kb, I2kb and
I3kb are the intensities of the 1, 2 and 3kb bands,
respectively.
Mating of meganuclease expressing clones and screening
in yeast
A colony gridder (QpixII, Genetix) was used for the
mating of yeast strains. Mutants were gridded on nylon
ﬁlters covering YPD plates, using a high gridding density
(about 20 spots/cm
2). A second gridding process was per-
formed on the same ﬁlters for the spotting of a second
layer consisting of reporter-harboring yeast strains for
each target. Membranes were placed on solid agar YPD
rich medium, and incubated overnight at 308C, to
allow mating. The ﬁlters were then transferred onto syn-
thetic medium, lacking leucine and tryptophan, with
galactose (2%) as the carbon source (and with G418 for
co-expression experiments), and incubated for 5 days at
378C, to select for diploids carrying the expression and
target vectors. Filters were then placed on solid agarose
medium with 0.02% X-Gal in 0.5M sodium phosphate
buﬀer, pH 7.0, 0.1% SDS, 6% dimethyl formamide
(DMF), 7mM b-mercaptoethanol, 1% agarose, and incu-
bated at 378C, to monitor b-galactosidase activity. Filters
were scanned and quantiﬁed with proprietary software.
Beta-galactosidase activity is directly associated with the
eﬃciency of homologous recombination. Experiments
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bination activities in yeast have shown that the recombi-
nation eﬃciency quantiﬁed in yeast is directly correlated
with the cleavage activity in vitro (unpublished data).
Extrachromosomal assay in CHO-K1 cells
CHO-K1 cells were transfected with the meganuclease
expression vectors and the reporter plasmid, in the pres-
ence of Polyfect transfection reagent in accordance with
the manufacturer’s protocol (Qiagen) The culture medium
was removed 72h after transfection, and 150ml of lysis/
detection buﬀer was added for b-galactosidase liquid assay
(typically, for 1l of buﬀer, we used 100ml of lysis buﬀer
(10mM Tris–HCl pH 7.5, 150mM NaCl, 0.1% Triton
X100, 0.1mg/ml BSA, protease inhibitors), 10ml of Mg
100  buﬀer (MgCl2 100mM, 2-mercaptoethanol 35%),
110ml of an 8mg/ml solution of ONPG and 780ml of
0.1M sodium phosphate pH 7.5). After incubation at
378C, we measured optical density at 420nm. The entire
process was performed on an automated Velocity11
BioCel platform.
Immuno-precipitation experiments
CHO-K1 cells were transfected with the meganuclease
expression vectors in the presence of Polyfect transfection
reagent according to the manufacturer’s (Qiagen) proto-
col. Cells were harvested 48h after transfection. We
avoided the disruption of heterodimers due to the use of
stringent buﬀers such RIPA, by resuspending cells in PBS
supplemented with a mixture of protease inhibitors (Santa
Cruz) and lysing them by successive freeze-thaw cycles.
After centrifugation (10min at 13000 g), the superna-
tant was recovered and the total protein concentration
was determined by the BCA assay. Volumes were adjusted
such that the protein concentration was identical (0.7mg/
ml) for the V2/V3 heterodimer and the V2
+/V3
  obligate
heterodimer. Both supernatants were then incubated
twice, for 12h each, with 15ml (equivalent to 7.5mgo f
antibody) of an anti-HA antibody coupled to agarose at
48C. The sample was then centrifuged (2min at 8000 g)
and 10ml of the supernatant were subjected to SDS–
PAGE and western blotting.
Targeting of a chromosomal reporter gene in
CHO-K1 cells
CHO-K1 cell lines harbouring the reporter system
were seeded at a density of 2 10
5cells per 10cm dish in
complete medium [Kaighn’s modiﬁed F-12 medium
(F12-K), supplemented with 2mM L-glutamine, penicillin
(100IU/ml), streptomycin (100mg/ml), amphotericin B
(Fongizone) (0.25mg/ml) (Invitrogen-Life Science) and
10% FBS (Sigma-Aldrich Chimie)]. The next day, cells
were transfected in the presence of Polyfect transfection
reagent (Qiagen). Cells were co-transfected with 2mgo f
LacZ repair matrix vector and various amounts of mega-
nuclease expression vector. After 72h of incubation at
378C, cells were ﬁxed by incubation in 0.5% glutaralde-
hyde at 48C for 10min, washed twice in 100mM phos-
phate buﬀer supplemented with 0.02% NP40 and
stained with the following staining buﬀer [10mM
phosphate buﬀer, 1mM MgCl2, 33mM potassium hexa-
cyanoferrate (III), 33mM potassium hexacyanoferrate
(II), 0.1% (w/v) X-Gal]. Plates were incubated overnight
at 378C and examined under a light microscope to deter-
mine the number of LacZ-positive cells. The frequency of
LacZ repair is expressed as a percentage and is calculated
as the number of LacZ-positive foci divided by the
number of transfected cells (5 10
5), corrected for the
transfection eﬃciency.
Cell survival assay
The CHO-K1 cell line was used to seed plates at a density
of 2 10
5cells per 10cm dish. The next day, various
amounts of meganuclease expression vectors and a con-
stant amount of GFP-encoding plasmid were used
to transfect the cells. GFP levels were monitored on
Days 1 and 6 after transfection, by ﬂow cytometry
(Guava EasyCyte, Guava Technologies). Cell survival is
expressed as a percentage and was calculated as a ratio:
(meganuclease-transfected cell expressing GFP on Day 6/
control transfected cell expressing GFP on Day 6), cor-
rected for the transfection eﬃciency determined on Day 1.
c–H2AX immunocytochemistry
For g-H2AX immunocytochemistry, CHO-K1 cells were
transfected with a mixture containing various amounts of
plasmid encoding a HA-tagged meganuclease, with DNA
levels made up to 4mg with empty vector, in the presence
of Polyfect reagent (Qiagen). Cells were ﬁxed 48h after
transfection, by incubation with 2% of paraformaldehyde
for 30min, and permeabilized by incubation for 5min at
room temperature in 0.5% Triton. Cells were washed and
incubated for 1h in 0.3% Triton buﬀer supplemented with
10% normal goat serum (NGS) and 3% BSA, to block
non-speciﬁc staining. Cells were then incubated for 1h at
RT with anti-g-H2AX (Upstate: 1/10000) and anti-HA
(Santa Cruz:1/200) antibodies diluted in Triton 0.3% in
PBS supplemented with 3% BSA and 10% NGS and then
for 1h with Alexa Fluor 488 goat anti-mouse (Invitrogen-
Molecular Probes: 1/1000) and Alexa Fluor 546 goat anti-
rabbit secondary antibodies diluted in 0.3% Triton in
PBS supplemented with 3% BSA, and 10% NGS.
Coverslips were incubated with 1mg/ml 40,6-diamino-20-
phenylindole (DAPI; Sigma), mounted and the g-H2AX
foci were visualized in transfected cells (HA-positive) by
ﬂuorescence microscopy. The inactive double-mutant
V2(G19S)/V3(G19S) heterodimer was used as a negative
control at a dose of 1mg of each expression plasmid.
Endogenous gene targeting experiments
The donor plasmid for gene targeting experiments con-
tained left and right homology arms generated by PCR
ampliﬁcation of the human RAG1 locus. An exogenous
DNA fragment was inserted between these two arms.
These sequences consisted of either a 1.7-kb DNA frag-
ment derived from a neomycin expression plasmid or a
10-bp DNA sequence containing an HindIII recognition
site. The human 293H cells (Invitrogen) were plated at a
density of 1 10
6cells per 10cm dish in complete medium
(DMEM supplemented with 2mM L-glutamine, penicillin
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(Fongizone: 0.25mg/ml, Invitrogen-Life Science) and
10% FBS). The next day, cells were transfected in the
presence of Lipofectamine 2000 transfection reagent
(Invitrogen) according to the manufacturer’s protocol.
Cells were co-transfected with 2mg of the donor plasmid
and 3mg of meganuclease expression vector. After 48h
of incubation at 378C, cells were treated with trypsin
and dispensed at a density of 10 or 100 cells per well in
96-well plates or re-plated and individual clones picked
and subsequently ampliﬁed. DNA was extracted with
the ZR-96 genomic DNA kit (Zymo research) according
to the manufacturer’s protocol. PCR ampliﬁcation reac-
tions were performed with the primers F2:50-AGGATCT
CCTGTCATCTCAC-30 and R2: 50-GCAGTGTTGCAG
ATGTCACAG-30, and F2:50-AGGATCTCCTGTCATC
TCAC-30 and R12: 50-CTTTCACAGTCCTGTACATCT
TGT-30 in order to detect the targeted integrations of the
10bp and 1700bp exogenous fragments, respectively. The
PCR products related to the 10bp integrations experi-
ments were further digested by the restriction enzyme
HindIII. Southern blot analysis was performed with geno-
mic DNA digested with HindIII and hybridized with an
830bp RAG1 speciﬁc probe binding outside of the right
homology arm of the donor plasmid.
RESULTS
Engineering of I-CreI derivatives cleaving a sequence
from the human RAG1 gene
We described here an artiﬁcial heterodimeric meganu-
clease derived from the I-CreI meganuclease that is capa-
ble of cleaving a DNA sequence from the human RAG1
gene, (12). We have further improved the cleavage activity
of this protein by random mutagenesis, as previously
described (32), resulting in the production of a new het-
erodimeric protein named, V2/V3. The V2 and V3 pro-
teins have the following mutations with respect to the
wild-type I-CreI sequence: N30R, Y33N, Q44A, R68Y,
R70S and I77R for V2 and K28N, Y33S, Q38R, S40R,
Q44Y, R70S, D75Q, I77V and E157G for V3. V2/V3
cleaves its cognate target eﬃciently in CHO-K1 cells
(Figure 1a), in our previously described extrachromoso-
mal assay based on meganuclease-induced recombination
by single-strand annealing (SSA) (17). However, the for-
mation of V2/V3 in target cells requires the simultaneous
production of V2 and V3, which also results in the forma-
tion of V2/V2 and V3/V3 homodimers, cleaving the LL
and RR targets, respectively (Figure 1a). These two homo-
dimeric species are therefore likely to decrease overall
speciﬁcity, by cleaving oﬀ target sequences. We used two
approaches to abolish homodimer formation.
Design of obligate heterodimers
We ﬁrst redesigned the dimerization interface to ensure
that only heterodimers could be produced. We have
previously described I-CreI derived obligate heterodimers
functional in vitro (36). However, the extensive design
resulted in a reduction of activity in vivo (data not
shown). Here, we used a stepwise approach to preserve
maximal activity. Several charged residues involved
in electrostatic interactions between monomers, including
Lys7, Glu8, Glu61, Lys96, Arg51 and Asp137, (Figure 1b)
were mutated, as previously described (36). We also
mutated the Gly19 residue, which has been shown to
aﬀect protein activity (32,33). In a stepwise approach, we
ﬁrst tested the impact of single mutations, such as K7E,
E8K, E61R, K96E, R51D, D137R and G19S. The single
mutationswereintroducedintotheV2andV3mutantsand
the activity of the resulting homodimeric proteins against
the two palindromic targets, LL or RR was monitored
by simple transfection in CHO-K1 cells, using the SSA-
based extrachromosomal assay described in Figure 1a.
Supplementary Figure 1 shows that neither the K7E nor
the E8K mutation signiﬁcantly aﬀected homodimer activ-
ity. In contrast, the E61R and K96E mutations greatly
decreasedhomodimer activityforbothV2andV3proteins,
although they had a greater impact on the V2 protein than
on the V3 protein. The G19S, R51D and D137R mutations
almost entirely abolished cleavage activity.
We then co-expressed the various V2 mutants with a
V3-derived partner bearing the compensatory mutation
in CHO-K1 cells (For example the V2 variant carrying
the K7E was associated with the V3 variant bearing the
E8K mutation). The ability of each pair to cleave the LR,
RR, or LL targets was monitored in our extrachromosa-
mal assay in CHO-K1 cells (Supplementary Figure 2) and
is expressed as a relative activity to the V2/V3 activity.
V2 and V3 co-expression results in cleavage of the three
LR, LL and RR targets as a result of the presence of the
heterodimer and the two homodimers. The co-expression
of V2/V3 variants with the R51D or D137R mutation
results in very low levels of LR activity and were thus
not further considered. The co-expression of V2 and V3
mutants carrying mutations at positions 61 and 96 leads to
a large decrease in homodimer activities, particularly for
the LL target, the cleavage of which was not detectable. A
signiﬁcant decrease of the activity against the LR target,
corresponding to 60% of the V2/V3 activity, was also
observed. When a V2 mutant carrying the K7E or E8K
mutations was co-expressed with a V3 mutant carrying the
compensatory mutations, heterodimer activity was not
aﬀected while homodimer activities were still relatively
strong. It can be noted that in the case of co-expression,
the LL cleavage activity due to the V2 E8K mutant was
much weaker than the initial V2 activity, despite the V2
E8K mutant being clearly active against the LL palindro-
mic target. Interestingly, the addition of the G19S muta-
tion to V2 or V3 resulted in the largest decrease in the
corresponding homodimer activity, with no signiﬁcant
decrease in the heterodimer activity (Supplementary
Figures 1 and 2). However, we could not identify any
symmetrical mutation that could be combined with
G19S, in order to inactivate both homodimers, but pre-
served the heterodimer’s activity.
With a view to obtaining true obligate heterodimers,
the two sets of mutations, K7E-E8K and E61R-K96E,
were combined with or without the G19S mutation. For
both I-CreI-derived variants, V2 and V3, the four double
mutants—K7E-E61R, E8K-E61R, K7E-K96E, E8K-
K96E—were produced. The homodimer activity of the
Nucleic Acids Research, 2009,Vol.37, No. 16 5409double mutants was monitored against the palindromic
targets LL and RR in CHO-K1 cells in our extrachromo-
somal assay, after the individual transfection of each
mutant. The activity of the four double mutants derived
from V2 against the LL target was much lower than that
of V2, almost reaching background levels (Figure 2a).
The V3-derived mutants also displayed lower levels of
activity, particularly those carrying the K96E mutation.
Combinations of mutant proteins carrying compensatory
mutations were then produced by co-expression in CHO-
K1 cells and activity against the LR target was monitored
(data not shown). All four active obligate heterodimers
had similar cleavage activity and the meganuclease
resulting from the co-expression of V2 E8K-E61R (V2
+)
with V3 K7E-K96E (V3
 ) was selected for further studies
and characterization.
The abolition of homodimer activities may result from
a lack of homodimer production or from the production
of a non-functional protein. We addressed this question by
determining the levels of diﬀerent proteins in CHO-K1
cells. An HA-epitope was added to the C-terminus of
the V2 and V2 E8K-E61R proteins and an S-Tag was
added to the C-terminus of the V3 and V3 K7E-K96E
proteins for this purpose. Protein levels were then moni-
tored by western blotting after the transfection of CHO-
K1 cells with a single mutant or with the two mutants
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Figure 1. Design of obligate heterodimers and single-chain molecules. (a) Extrachromosomal assay used to monitor the activity of the engineered
meganucleases in CHO-K1 cells. A meganuclease cleavage site (black box) is placed between two direct repeats in a reporter plasmid. Cleavage of the
target site induces tandem-repeat recombination, thereby restoring a functional b-galactosidase gene. V2/V3: co-expression of the V2 and V3 mutant
constructs; V2 and V3: expression of V2 and V3, respectively; Ø: empty vector. Cleavage activity was monitored against the palindromic targets LL
(gray bars) and RR (white bars), and the non-palindromic target LR (black bars). The cleavage activity of I-SceI with its target is shown as a positive
control (hatched bar). Bars indicate the mean   SD (n=3). (b) Engineered positions are indicated on the structure of the I-CreI meganuclease bound
to its DNA substrate (PDB code 1G9Y). The three monomer–monomer interactions targeted in the obligate heterodimer design are highlighted. In
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+/V3
  heterodimers. In
co-expression experiments, the two mutants forming the
V2/V3 heterodimer and the two proteins constituting the
V2
+/V3
  obligate heterodimer were produced in very sim-
ilar amounts (Figure 2b). This similarity is consistent with
the similarity in the activity of the two heterodimers
against the LR target. The diﬀerences in the fate of
individual proteins were much more striking. The V2
and V3 were produced in amounts equivalent to those
observed for the V2/V3 heterodimer. By contrast, the
V2
+ (V2 E8K-E61R) protein was not detected at all
whereas the V3
  (V3 K7E-K96E) protein level was pro-
duced in small amounts, corresponding to no more than
one ﬁfth the amount of V3 protein. Immunoprecipitation
experiments were used to assess the presence or absence of
the V3
  homodimer when both partners of the V2
+/V3
 
heterodimer were expressed together. The lysates of CHO-
K1 cells co-transfected either with the V2 and V3 coding
vectors or with the V2
+ and V3
  coding vectors were
depleted of proteins carrying the HA epitope (V2 or
V2
+) by successive incubations with an anti-HA antibody.
The supernatants were analyzed by western blotting with
anti-HA and anti-S-Tag antibodies (Figure 2c). After two
successive immunoprecipitations, the two supernatants
were entirely depleted of any HA-tagged proteins. In the
case of the V2/V3 heterodimer, 50% of the S-Tag-labeled
proteins (lane S2) were recovered after two successive
immunoprecipitations, as shown by quantitative densito-
metry. This protein fraction corresponds to the V3/V3
homodimer. For the V2
+/V3
  heterodimer, almost no
V3
  homodimer formation was detected, as revealed by
the barely detectable signal after the ﬁrst immunoprecipi-
tation, showing that both V2
+ and V3
  are required for
stabilization and folding into a functional heterodimer.
Design of single-chain meganucleases
We and others have already described single-chain ver-
sions of I-CreI (37,38), an alternative approach to abolish-
ing homodimer formation and activity. We designed a
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Nucleic Acids Research, 2009,Vol.37, No. 16 5411series of new single-chain I-CreI derivatives, which main-
tain maximal levels of activity, by connecting the C-term-
inal part of a ﬁrst monomer to the N-terminal part of a
second monomer with a series of linkers diﬀering in length
and in their potential to form secondary structures (a-helix
or type II polyproline helix). The activity of 18 such novel
proteins was assessed (Table 1) in a yeast assay described
in previous studies (17,37). A 32 amino acid linker with a
predicted a-helix was eventually selected (number 18 in
Table 1). In order to investigate the impact of the position
of each monomer within the single-chain (sc) molecule and
the impact of the G19S mutation, we produced the six
constructs scV2-V3, scV2(G19S)-V3, scV2-V3(G19S),
scV3-V2, scV3(G19S)-V2, scV3-V2(G19S) and assessed
their ability to cleave the LL, RR, and LR targets
(Supplementary Figure 3). All six molecules had high
levels of activity against the LR target, equivalent to the
activity of the V2/V3 heterodimer whereas cleavage of
the LL and RR targets was either abolished or strongly
decreased. These results demonstrate that the single-chain
design favors intra-molecular interactions between the two
I-CreI-derived moieties.
However, residual cleavage of the LL palindromic
target was still observed for some constructs. We hypoth-
esize that inter-molecular interactions could still occur,
resulting in the generation of an active nuclease. The
elimination of the LL cleavage activity could be achieved
by the introduction of the G19S mutation into the V2
mutant or by the introduction of the engineered electro-
static interactions (Supplementary Figure 3). Finally,
we combined the single-chain design and the new dimer-
ization interface, to produce the scV3
 -V2
+ and scV3
 -
V2
+ (G19S) molecules. These molecules were compared
with previous constructs in an extrachromosomal in vivo
assay (Figure 3a) or in vitro cleavage assay (Figure 3b).
These two molecules had cleavage proﬁles very similar to
those of their scV3-V2 and scV3-V2(G19S) counterparts,
with G19S having again a strong impact on LR cleavage
in CHO-K1 cells. The scV3-V2(G19S) and scV3
 -
V2
+(G19S) molecules and the two obligate heterodimers
V2
+/V3
  and V2
+ (G19S)/V3
 , performed similarly, dis-
playing high levels of cleavage activity and no detectable
activity against the palindromic targets.
Obligate and single-chain meganucleases are active in
a gene targeting assay in CHO-K1 cells
We compared the abilities of diﬀerent V2/V3 variants to
stimulate homologous gene targeting (GT) in a previously
described chromosomal reporter system (32), in CHO-K1
cells bearing a single chromosomal copy of the LacZ gene
interrupted by the LR target (Figure 4a). GT frequency
was monitored over a wide dose range. The V2/V3 hetero-
dimer induced GT with a frequency of up to 0.27%.
The G19S, obligate heterodimer, and G19S obligate het-
erodimer versions increased this frequency up to 0.8%
(Figure 4a). However, the frequency of GT observed
with these molecules rapidly decreased at higher doses,
suggesting potential adverse eﬀects. By contrast, the two
single-chain molecules were the most similar in behavior
to the I-SceI meganuclease, and were highly eﬀective over
a broad range of doses, their activity level reaching a near
plateau at about 100ng of expression vector. Western
blotting analysis demonstrated that this plateau was not
due to an expression or stability artifact, for all the
tested meganucleases were produced in similar amounts
(Figure 4b and data not shown). We also failed to detect
any truncated products (Figure 4b and data not shown),
showing that the linker of the single-chain molecules was
not subjected to proteolytic cleavage in CHO-K1 cells.
Obligate heterodimer and single-chain designs decrease
toxicity and off-site cleavage
Toxicity is a major issue for DSB-induced recombination
technology, particularly for therapeutic applications,
Table 1. Amino acid sequences of the linker regions that were inserted between two I-CreI-variants
V2 and V3
Number Size (aa) Primary sequence Activity in yeast
1 22 AA(GGGGS)4 ++
2 35 AAGKSSDSKGIDLTNVTLPDTPTYSKAASDAIPPA +++
3 30 AAGLEYPQAPYSSPPGPPCCSGSSGSSAGCS +++
4 30 AAGLSYHYSNGGSPTSDGPALGGISDGGAT +++
5 27 AAGDSSVSNSEHIAPLSLPSSPPSVGS +++
6 25 AAGASQGCKPLALPELLTEDSYNTD ++
7 24 AAGNPIPGLDELGVGNSDAAAPGT ++
8 23 AAGAPTECSPSALTQPPSASGSL +
9 27 AA(GGGGS)5 ++
10 17 AA(GGGGS)2 +
11 12 AA(GGGGS)2 +
12 17 AAGQVTSAAGPATVPSG +
13 19 AAGGSPLKPSAPKIPIGGS +
14 33 AAGGSPLKPSAPKIPIGGSPLKPSAPKIPIGGS +++
15 15 AAGGSPLSKPIPGGS +
16 25 AAGGSPLSKPIPGGSPLSKPIPGGS ++
17 31 AAGGSDKYNQALSERRAYVVANNLVSGGGGS +++
18 32 AAGGSDKYNQALSKYNQALSKYNQALSGGGGS +++
The activity of the resulting single-chain molecule was assessed in yeast. The linker selected for the
RAG single-chain design is shown in underlined typeface.
5412 Nucleic Acids Research, 2009, Vol. 37,No. 16for which the activity/toxicity ratio is of major concern.
The toxicity of the RAG1 meganucleases was evaluated by
adapting a previously described cell survival test (11) to
the CHO-K1 cells used for the activity dose response
assay. The V2(G19S)/V3(G19S) heterodimer was used as
a control for non-toxicity, as this molecule was completely
inactive in all our assays (Figure 4a and data not shown).
At the active dose ( 100ng, the dose at which the mega-
nucleases displayed their maximum level of activity
Figure 4b), toxicity was barely detectable with all mega-
nucleases (Figure 5a). However, the V2/V3 heterodimer
displayed signiﬁcant toxicity at higher doses, which was
partly alleviated by the obligate heterodimer design (but
not by the G19S mutation), and further decreased by the
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LR (black bars), LL (gray bars) and RR (white bars) is shown as a percentage of the activity resulting from V2/V3 co-expression. V2+, mutant V2
(E8K, E61R); V3 , mutant V3 (K7E, K96E); sc, single-chain molecule; Ø: empty vector. Bars indicate the mean   SD (n=3). (b) In vitro cleavage
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Nucleic Acids Research, 2009,Vol.37, No. 16 5413single-chain designs, with the best version closely mimick-
ing the pattern obtained with I-SceI, the most speciﬁc
endonuclease to date.
The toxicity of sequence-speciﬁc endonucleases is
usually attributed to oﬀ-site cleavage, which can result
in mutations, deletions, translocations and other gross
genomic alterations (9). We evaluated oﬀ-site cleavage,
by monitoring the formation of phosphorylated H2AX
histone (g-H2AX) foci. g-H2AX focus formation is one
of the ﬁrst responses of the cell to DNA DSBs and pro-
vides a convenient means of monitoring DSBs in living
cells (40). CHO-K1 cells were transfected with two doses
of meganuclease expression vectors (active dose and
10-fold excess) and g-H2AX was monitored by image ana-
lysis (Figure 5b). At the active dose, with the exception of
V2 (G19S)/V3, the expression of the various RAG mega-
nucleases induced between 1 and 5 g-H2AX foci per trans-
fected cell, as did I-SceI. For discrimination between the
diﬀerent designs, we analyzed the induction of g-H2AX
foci when meganucleases were produced in large excess
(10-fold excess). The production of signiﬁcant numbers
of foci was observed for the V2/V3 and V2 (G19S)/V3
heterodimers at an excess dose (Figure 5b), with up
to 70% of the transfected cells showing more than 25
g-H2AX foci per cell. However, the obligate heterodimer
and single-chain designs drastically reduced this eﬀect,
close to the level found with I-SceI and the V2(G19S)/
V3(G19S) proteins.
A single-chain meganuclease induces high levels of
homologous gene targeting at the endogenous
human RAG1 locus
Finally, we evaluated the ability of the scV3
 -V2
+(G19S)
engineered meganuclease to stimulate homologous recom-
bination at the endogenous RAG1 locus in human cells.
We designed two repair plasmids. The ﬁrst contained
10bp of exogenous DNA (containing a single HindIII
restriction site) ﬂanked by two sequences, 900bp and
500bp in length, homologous to the human RAG1 locus.
The second carried 1700bp of exogenous DNA ﬂanked
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5414 Nucleic Acids Research, 2009, Vol. 37,No. 16by two homology arms of 2.0kb and 1.6kb in length. We
assessed the ability of the scV3
 -V2
+(G19S) protein to
induce targeted events at the endogenous locus (Figure 6).
After co-transfection with the meganuclease-encoding
vector and the donor repair plasmid, 293H cells were
cloned and cultured in 96-well microplates and analyzed
by PCR. PCR screening is exempliﬁed in Figure 6b
and c and summarized in Table 2. Positive clones were
C
e
l
l
 
s
u
r
v
i
v
a
l
 
(
%
)
Amount of transfected plasmid (ng)
gH2AX Foci cells content
C
e
l
l
s
 
(
%
)
0
20
40
60
80
100
120
0
1X ACTIVE DOSE
0
20
40
60
80
100
No foci 1 to 5 11 to 25 > 25
10X ACTIVE DOSE
No foci 1 to 5 6 to 10 11 to 25 > 25
gH2AX Foci cells content
C
e
l
l
s
 
(
%
)
0
20
40
60
80
100
V2(G19S)/V3(G19S)
I-SceI
V2/V3
V2(G19S)/V3
V2+/V3–
scV3-V2(G19S)
sc V3–-V2+(G19S)
V2(G19S)/V3(G19S)
I-SceI
sc V3–-V2+(G19S)
scV3-V2(G19S)
V2+/V3–
V2(G19S)/V3
V2/V3
(a)
(b)
200 400 600 800 1000
6 to 10
Figure 5. Evaluation of the toxicity of meganucleases. (a) Toxicity of the engineered meganucleases, as monitored by a cell survival assay. Various
amounts of meganuclease expression vector and a constant amount of plasmid encoding GFP were used to co-transfect CHO-K1 cells. Cell survival
is expressed as the percentage of cells expressing GFP 6 days after transfection, as described in the ‘Materials and Methods’ section. The inactive
V2(G19S)/V3(G19S) heterodimer is shown as a control for non-toxicity. (b) DNA damage was visualized by the formation of g-H2AX foci at
DNA double-strand breaks. CHO-K1 cells were transfected with a plasmid encoding the meganuclease fused to an HA epitope at the active dose
(quantity used for maximal activity) or 10 times the active dose. The inactive V2(G19S)/V3(G19S) heterodimer was used as a control (1mg of each
expression plasmid). The number of g-H2AX foci in transfected cells (HA positive) was determined for each condition. Representative images below
each class illustrate the diﬀerent classes of g-H2AX foci in CHO-K1 cells transfected with meganuclease: Red, HA labeling; green, g-H2AX foci; and
blue, DAPI staining.
Nucleic Acids Research, 2009,Vol.37, No. 16 5415ampliﬁed, double-checked by PCR, and analyzed by
Southern blotting. The insertion of the 10bp and
1700bp fragments was conﬁrmed by Southern blotting
in 93% (13/14) and 82% (9/11) of the initial PCR positive
clones, respectively (see examples in Figure 6d and e).
Three clones were not conﬁrmed by Southern blot or by
PCR after ampliﬁcation, and were considered as false
positives. We hypothesize that this is due to the presence
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Figure 6. Targeted integration at the endogenous RAG1 locus, driven by a single-chain meganuclease. (a) Experimental outline and diagram of the
gene targeting strategy used at the endogenous RAG1 locus. The RAG1 target sequence is located just upstream from the coding sequence for exon 2
of the Rag1 protein. Exon 2 is boxed, with the open reading frame in white. Cleavage of the native RAG1 gene by the meganuclease yields a
substrate for homologous recombination, which may use the repair plasmid containing either 10bp or 1.7kb of exogenous DNA. The 10-bp DNA
fragment (containing a single HindIII restriction site) is ﬂanked by two sequences, 900bp and 500bp in length, homologous to the human RAG1
locus. The 1700bp DNA fragment is ﬂanked by two homology arms of 2.0kb and 1.6kb in length. Human 293H cells were transfected with 3mgo f
scV3
 -V2
+(G19S) meganuclease expression plasmid and 2mg of the repair substrate, cultured without selection for 48h, re-plated, and individual
clones picked and ampliﬁed. Targeted integration events were detected by PCR ampliﬁcation and subsequently conﬁrmed by Southern blotting.
(b) Example of a screen for targeted integration events with a repair plasmid containing 10bp of exogenous DNA. Genomic DNA derived from
individual clones (a–i) obtained after transfection with a meganuclease expression plasmid and a repair plasmid was ampliﬁed by PCR and digested
with HindIII.   is the negative control (non-transfected cells). PCR primers positions are indicated by simple arrows, with one primer binding
outside the region of homology used in the repair plasmid. On the gel, bands correlated with a targeted event are indicated with a black triangle (c)
Example of a PCR screen for targeted integration events with the repair plasmid containing 1700bp of exogenous DNA. PCR analysis of 11 diﬀerent
samples (1–11), + indicates positive control (a recombinant plasmid), and   is the negative control (non-transfected cells). (d) Southern blot analysis
of six individual clones (1–6) that were positive in the PCR screen for the integration of the 10bp exogenous fragment, analyzed together with DNA
from non-transfected cells ( ). The locus maps indicate the restriction pattern of the wild-type locus (5.3kb) and the targeted locus (3.0kb). (e)
Southern blot analysis of three PCR-positive (1–3) and two PCR-negative clones (4–5) samples derived from single transfected cells are analyzed,
together with DNA from non-transfected cells ( ). The locus maps indicate the restriction pattern of the wild-type locus (5.3kb) and the targeted
locus (3.4kb). Probes are indicated by a solid black box. H, genomic location of HindIII cleavage sites.
5416 Nucleic Acids Research, 2009, Vol. 37,No. 16of a mixed colony resulting from a contamination of adja-
cent cells during the picking of individual clones, followed
by loss of the positive clone during ampliﬁcation.
Nevertheless, meganuclease-mediated gene insertion
could be achieved in up to 6% of the transfected cells
(Table 2). In contrast, no GT event was detected in the
absence of meganuclease, with both repair matrices, out of
a total of 582 (10bp insertion matrix) and 445 (1700bp
insertion matrix) clones.
In order to screen a larger number of cells transfected
with the repair matrix alone (1700bp insertion matrix), we
also analyzed pools of transfected cells. Our PCR test was
ﬁrst assessed for its ability to detect positives in non-clonal
populations: targeted cells displaying the 1700bp insertion
were diluted in naive 293H cells and analyzed by PCR to
test for the presence of the insertion. Targeted cells could
still be detected even when diluted in a 1000-fold excess of
non-targeted cells (data not shown). Then, 96-well plates
were seeded with cells transfected with the repair matrix
alone, at density of 10 or 100 cells per well, and each pool
was analyzed by PCR. Again, no positives were identiﬁed
in the absence of meganuclease among more than 40000
analyzed cells (Table 2). These results demonstrate that
gene targeting can be achieved with a high eﬃciency and
without selection at an endogenous locus in mammalian
cells using an engineered meganuclease.
DISCUSSION
One of the most exciting prospects for meganuclease-
induced gene targeting lies in its potential for use in molec-
ular medicine, although such applications are highly
demanding in terms of safety. The use of homodimeric
scaﬀolds, such as I-CreI, to produce a heterodimeric
meganuclease that recognizes and cleaves an asymmetric
DNA sequence requires the engineering of two diﬀerent
monomers. Heterodimer formation is then obtained by
producing the two monomers simultaneously in the
cell. However, this leads to the presence of a mixture
of enzymes within the cells and the two homodimer
by-products could favor oﬀ-site cleavage jeopardizing
overall meganuclease speciﬁcity. Two diﬀerent strategies
have been used to tackle this problem. The ﬁrst one con-
sists in the modiﬁcation of the dimerization interface, to
produce obligate heterodimers. Such an approach has pre-
viously been applied to zinc-ﬁnger nucleases, (34,35),
resulting in improvements in speciﬁcity, and to I-CreI-
derived obligatory heterodimers (36). Natural evolution
has selected an alternative solution, single-chain meganu-
cleases (41,42) such as I-SceI, which is considered to be
the gold standard in terms of speciﬁcity. Artiﬁcial single-
chain molecules derived from wild-type homodimeric
LAGLIDADG meganucleases have already been
described by us and others (37,38).
Extensive redesign can result in loss of activity. In
this study, we tried to avoid any trade oﬀ between activity
and speciﬁcity, by simplifying the designs. A previously
described I-CreI-derived obligate heterodimer (36) dis-
played mutations at positions Lys7, Asp8, Glu61 and
Lys96, but also in a hydrophobic patch made by several
residues. In the new obligate heterodimers, we engineered
only two electrostatic interactions (Lys7-Asp8 and
Glu61-Lys96) that proved suﬃcient to destabilise homo-
dimer formation, without any loss of activity for the
heterodimer. For the single-chain designs, we previously
connected two I-CreI monomers with a short linker (37),
but the use of this shorter sequence was only made possi-
ble by truncating the ﬁrst I-CreI monomer by one third.
Here, we favored the use of long linkers, allowing for
minimal modiﬁcation of both monomers, as described
recently (38). In addition, we could create a functional
single-chain molecule carrying the obligate heterodimer
speciﬁc mutations, a design that more closely mimics
natural single-chain meganucleases, whose diverged
LAGLIDADG regions are able to interact together in
a ‘heterodimer-like’ manner, but can no longer form
homodimers (22).
A G19S mutation had a striking eﬀect on both dimers
and single-chain molecules. This mutation was previously
found to decrease the activity of dimers when it was
Table 2. Gene targeting experiments performed with scV3
 -V2
+(G19S) engineered to target the human RAG1 locus
Insertion
length (bp)
Meganuclease Cells/
well
Total no.
of cells
analyzed
PCR
Positives
Conﬁrmed by
Southern blot
conﬁrmed/analyzed
Recombination
frequency(%)
10 + 1 183 7 (3.8%) 6/6 3.8%
10 + 1 376 13 (3.5%) 7/8 3.0%
10 – 1 325 0
10 – 1 257 0
1700 + 1 94 5 (5.3%) 3/5 3.2%
1700 + 1 376 23 (6.1%) 6/6 6.1%
1700 – 1 94 0
1700 – 1 351 0
1700 – 10 2560 0
1700 – 10 1880 0
1700 – 100 37000 0
Each line corresponds to the results of an independent experiment. Cells/well: number of cells used in the study of clones (1 cell/well) or pools (10
or 100 cells/well) of transfected cells. Recombination frequencies are calculated as the frequency of PCR positives, corrected by the ratio of clones
conﬁrmed by Southern blotting.
Nucleic Acids Research, 2009,Vol.37, No. 16 5417present in the two monomers, but to increase this activity
when present only in one monomer (our unpublished
data). Consistently, G19S strongly impaired or abolished
the activity of the V2(G19S)/V2(G19S), V3(G19S)/
V3(G19S) and V2(G19S)/V3(G19S) molecules (Supple-
mentary Figure 2 and Figure 4). The Gly19 residue is
found at the end of the LAGLIDADG helix, close to
the active site, and its change for a Serine substitutes a
hydrogen atom by a more voluminous side chain with a
polar hydroxyl group. Thus, the inhibition of G19S/G19S
dimer activity could be explained by a rearrangement of
the interhelical packing that disrupts the catalytic center.
In the scV3-V2(G19S) molecule, G19S could further
impair cleavage of the LL target, possibly by alleviating
any possible functional interactions between V2 moieties
from diﬀerent molecules. Activity enhancement is more
diﬃcult to explain. A similar eﬀect had been observed
previously with a heterodimer carrying a G19A mutation
(32). In this study, G19S enhanced the activity of the
V2/V3 heterodimer in the GT assay in CHO-K1 cells
(Figure 4), but not in vitro (Figure 3b), suggesting that
the mutation does not directly impact the speciﬁc activity
of the protein. Improvement of the scV3-V2 by this sole
mutation was also spectacular [compare scV3-V2 and
scV3-V2(G19S) in Figure 3]. Further characterization
will be necessary to understand the impact of the G19S
mutation.
In their ﬁnal versions, both obligate heterodimer and
single-chain designs displayed high levels of activity,
lower toxicity and minimal numbers of oﬀ-site cleavage
events. Even at high doses (10-fold the dose required
for optimal activity), these designs largely prevented the
toxicity and g–H2AX foci formation observed with both
the V2/V3 and V2 (G19S)/V3 heterodimers. The single-
chain designs (with or without obligate heterodimer muta-
tions) appeared signiﬁcantly superior to the obligate het-
erodimer in the GT assay in CHO-K1 cells, wherein
single-chain molecules displayed high activity over a
much broader dose range. It is diﬃcult to explain these
diﬀerences: whereas the obligatory heterodimer displayed
a slightly higher toxicity than the single chain in the cell
survival assay (Figure 5a), the g-H2AX foci assay did not
show any diﬀerence between the two designs (Figure 5b).
These discrepancies could illustrate the limitations of the
g-H2AX foci assay, in which high levels of background
observed in immortalized cell lines could hide signiﬁcant
diﬀerences between endonucleases.
These diﬀerences need to be conﬁrmed with other engi-
neered proteins cleaving diﬀerent targets. Nevertheless,
single-chain molecules have the major advantage of
alleviating the problems associated with the control of
co-expression. Promising results have also been obtained
for the characterization of new scaﬀolds derived from nat-
ural monomeric endonucleases, such as I-DmoI (22,30,33)
and I-AniI (43,44), hybrid I-DmoI/I-CreI proteins (37,45),
and an hybrid of the S. cerevisiae PI-SceI protein and its
Candida tropicalis homologue (18), and single-chain mega-
nucleases, natural or artiﬁcial, represent a new generation
of engineered endonucleases for genome engineering.
In the present study, the properties of the RAG1 single-
chain meganucleases place these molecules among the best
molecular scissors available for genome surgery strategies.
Engineered meganucleases have been used to target chro-
mosomal reporter genes in mammalian cells (32,33), but
this is the ﬁrst time that the engineering of an endogenous
gene by such proteins has been reported. Gene targeting
was observed in 3–6% of total transfected cells. These
endonucleases should facilitate gene correction therapy
for monogenetic diseases, such as SCID.
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